Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Integrative Analysis of FISH, Transcriptomics and Mutational Status Predicts Responsiveness to Novel Agents in Multiple Myeloma

Cecilia Bonolo De Campos, PhD, Caleb K Stein, PhD, Nathalie Meurice, PhD, Laura Ann Bruins, BS, Joachim L Petit, PhD, Alysia N Polito, BS, Gregory J Ahmann, BS, Shulan Tian, MS, PhD, P. Leif Bergsagel, MD, Esteban Braggio, PhD, A. Keith Stewart, MB, ChB

Blood (2019) 134 (Supplement_1): 574.

https://doi.org/10.1182/blood-2019-130977

Published: 2019

Journal Articles

Therapeutic Stratification of PTEN-MYC Axis Appears to be Promising for Molecular Targeted Therapies in Refractory and Relapsed T-Cell Acute Lymphoblastic Leukemia

Heinz Ahlert, MSc, BSc, Sanil Bhatia, PhD, Marc Remke, MD, Melf Sönnichsen, M.Sc., Niklas Dienstbier, M.Sc., Ute Fischer, PhD, Julia Hauer, MD, Arndt Borkhardt, MD

Blood (2019) 134 (Supplement_1): 3883.

https://doi.org/10.1182/blood-2019-128136

Published: 2019

Journal Articles

Classification and Prognosis of Central Nervous System Involvement in Erdheim-Chester Disease

Fleur Cohen-Aubart, MD PhD, Ahmed Idbaih, MD PhD, Damien Galanaud, MD PhD, Bruno Law-Ye, MD, Jean-François Emile, MD PhD, Frédéric Charlotte, MD, Jean Donadieu, MD PhD, Zahir Amoura, MD MSc, Julien Haroche

Blood (2019) 134 (Supplement_1): 4272.

https://doi.org/10.1182/blood-2019-130606

Published: 2019

Journal Articles

Geriatric Assessment (GA) Measures and Patient-Reported Outcomes (PROs) Among Older Adults Treated in a Phase 1b Study for Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Heidi D. Klepin, MD MS, Avrita Campinha-Bacote, Wan-Jen Hong, Patrick Phuong, Jue Wang, Mehrdad Mobasher, MD MPH, Peter Trask

Blood (2018) 132 (Supplement 1): 4076.

https://doi.org/10.1182/blood-2018-99-116038

Published: 2018

Journal Articles

Characterizing Population Heterogeneity and Signaling Changes in Chronic Myeloid Leukemia Stem and Progenitor Cells upon Combined Treatment with Imatinib and MEK Inhibitors Using Quantitative Single Cell Phospho-Imaging

Anna Reister Schultz, BS, Thomas Jacob, Christopher A. Eide, Samantha L Savage, Motomi Mori, PhD, Jeffrey W. Tyner, PhD, Cristina E. Tognon, PhD, Tania Q. Vu, Brian J. Druker, MD

Blood (2018) 132 (Supplement 1): 4248.

https://doi.org/10.1182/blood-2018-99-115387

Published: 2018

Journal Articles

BCL-2 Inhibitor Venetoclax (ABT-199) and MEK Inhibitor GDC-0973 Synergise to Target AML Progenitors and Overcome Drug Resistance with the Use of PET Scanning in a Mouse Model of HR-MDS to Monitor Response to Treatment

Rose Ann Padua, PhD, Laure Sarda-Mantel, MD PhD, Mathieu Chiquet, BSc, Claire Kappel, BSc, Patricia Krief, PhD, Niclas Setterblad, PhD, Fortune Hontonnou, BSc, Benoit Hosten, PhD, Nicolas Vignal, BSc, Fabien Zassadowski, PhD, Bruno Cassinat, PharmD, PhD, Panhong Gou, BSc, Stephane Giraudier, MD PhD, Marina Y. Konopleva, MD PhD, Michael Andreeff, MD PhD, Marika PLA, PhD, Lionel Ades, MD PhD, Pierre Fenaux, MD PhD, Christine Chomienne, MD PhD

Blood (2018) 132 (Supplement 1): 5497.

https://doi.org/10.1182/blood-2018-99-114212

Published: 2018

Journal Articles

Safety, Efficacy, Pharmacokinetic (PK) and Biomarker Analyses of BCL2 Inhibitor Venetoclax (Ven) Plus MDM2 Inhibitor Idasanutlin (idasa) in Patients (pts) with Relapsed or Refractory (R/R) AML: A Phase Ib, Non-Randomized, Open-Label Study

Blood (2018) 132 (Supplement 1): 767.

https://doi.org/10.1182/blood-2018-99-116013

Published: 2018

Journal Articles

Preliminary Results from a Phase Ib Study Evaluating BCL-2 Inhibitor Venetoclax in Combination with MEK Inhibitor Cobimetinib or MDM2 Inhibitor Idasanutlin in Patients with Relapsed or Refractory (R/R) AML

Naval Daver, MD, Daniel A. Pollyea, MD, Karen W.L. Yee, MD, Pierre Fenaux, MD PhD, Joseph M. Brandwein, MD FRCPC, Norbert Vey, Giovanni Martinelli, Kevin R Kelly, MD PhD, Gail J. Roboz, MD, Jacqueline S. Garcia, Arnaud Pigneux, MD PhD, Smita Kshirsagar, Monique Dail, Jue Wang, Mehrdad Mobasher, Lin-Chi Chen, Wan-Jen Hong, Marina Konopleva, MD PhD, Michael Andreeff, MD PhD

Blood (2017) 130 (Supplement 1): 813.

https://doi.org/10.1182/blood.V130.Suppl_1.813.813

Published: 2017

Journal Articles

Phase 2 Trial of Single-Agent Cobimetinib for Adults with BRAF V600-Mutant and Wild-Type Histiocytic Disorders

Eli L Diamond, MD, Benjamin H Durham, MD BS, Ahmet Dogan, MD PhD, David M. Hyman, MD, Raajit K. Rampal, MD PhD, Gary Ulaner, MD, Lynn Brody, MD, Omar Abdel-Wahab, MD

Blood (2017) 130 (Supplement 1): 257.

https://doi.org/10.1182/blood.V130.Suppl_1.257.257

Published: 2017

Journal Articles

BCL-2 Inhibition with ABT-199 Shows Efficacy in AML Cell Lines with Synergistic Effects upon Addition of the MEK Inhibitor GDC-0973 and Prolongs Survival in an NAS/BCL-2-Mediated Mouse Model of AML Post-MDS

Rose Ann Padua, PhD, Mathieu Chiquet, BSc, Qi Zhang, PhD MD, Claire Kappel, Patricia Krief, PhD, Niclas Setterblad, PhD, Dr Omidvar, BSc, MSc, PhD, Marina Konopleva, MD PhD, Michael Andreeff, MD PhD, Marika PLA, PhD, Lionel Ades, MD PhD, Pierre Fenaux, MD PhD, Christine Chomienne, MD PhD

Blood (2017) 130 (Supplement 1): 2613.

https://doi.org/10.1182/blood.V130.Suppl_1.2613.2613

Published: 2017

Journal Articles

Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study)

Fleur Cohen Aubart, Jean-François Emile, Fabrice Carrat, Frédéric Charlotte, Neila Benameur, Jean Donadieu, Philippe Maksud, Ahmed Idbaih, Stéphane Barete, Khê Hoang-Xuan, Zahir Amoura, Julien Haroche

Blood (2017) 130 (11): 1377–1380.

https://doi.org/10.1182/blood-2017-03-771873

Published: 2017

Includes: Supplemental data

Journal Articles

PI3K and MEK Inhibition in Hypodiploid Acute Lymphoblastic Leukemia

Evan Comeaux, PhD, Wenwei Lin, PhD, Taosheng Chen, PhD, Burgess Freeman, III, PharmD, Charles G. Mullighan, MBBS, MSc, PhD

Blood (2016) 128 (22): 1635.

https://doi.org/10.1182/blood.V128.22.1635.1635

Published: 2016

Journal Articles

Upregulation of MAPK/MCL-1 Maintaining Mitochondrial Oxidative Phosphorylation Confers Acquired Resistance to BCL-2 Inhibitor Venetoclax in AML

Qi Zhang, MD PhD, Lina Han, MD PhD, Ce Shi, MD PhD, Rongqing Pan, MS, Man Chun John MA, PhD, Jeremy Ryan, PhD, Stephen E Kurtz, PhD, Hong Mu, MD PhD, Vivian Ruvolo, MS, Helen Ma, MS, Michael Andreeff, MD PhD, Yingchang Mi, MD PhD, Jeffrey W. Tyner, PhD, Joel Leverson, Anthony Letai, MD PhD, Richard Eric Davis, MD, Marina Konopleva, MD PhD

Blood (2016) 128 (22): 101.

https://doi.org/10.1182/blood.V128.22.101.101

Published: 2016

Journal Articles

Targeting MAPK Signaling Pathway with Cobimetinib (GDC-0973) Enhances Anti-Leukemia Efficacy of Venetoclax (ABT-199/GDC-0199) in Acute Myeloid Leukemia Models

Lina Han, MD PhD, Qi Zhang, MD PhD, Ce Shi, MD PhD, Antonio Cavazos, MS, Vivian Ruvolo, MS, Joel Leverson, Dail Monique, PhD, Darren C. Phillips, PhD, Jun Chen, MD PhD, Sha S Jin, Rodrigo Omar Jacamo, PhD, Naval Daver, MD, Elias J. Jabbour, MD, Hagop M. Kantarjian, MD, Michael Andreeff, MD PhD, Deepak Sampath, PhD, Marina Konopleva, MD PhD

Blood (2016) 128 (22): 97.

https://doi.org/10.1182/blood.V128.22.97.97

Published: 2016

Journal Articles

Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms

Benjamin Heath Durham, MD BS, Eli L. Diamond, MD, Julien Haroche, MD PhD, Zhan Yao, PhD, Jing Ma, PhD, Sameer A. Parikh, MD, John Choi, Eunhee Kim, PhD, Fleur Cohen-Aubart, Stanley Chun-Wei Lee, Yijun Gao, Jean-Baptiste Micol, MD, Patrick Campbell, MD PhD, Michael P. Walsh, Brooke Sylvester, Igor Dolgalev, Aminova Olga, Adriana Heguy, Paul Zappile, Joy Nakitandwe, BSc,MSc,PhD, James Dalton, BS, David W Ellison, MD, Juvianee Estrada-Veras, Mario Lacouture, William A. Gahl, MD PhD, Phil Stephens, PhD, Vincent A. Miller, MD, Jeffrey Ross, Siraj Ali, Sebastien Héritier, Jean Donadieu, MD PhD, David Solit, MD, David M. Hyman, Jose Baselga, MD PhD, Filip Janku, MDPhD, Barry S. Taylor, PhD, Christopher Y. Park, MD, PhD, Ahmet Dogan, MD PhD, Zahir Amoura, Jean-Francois Emile, Raajit K. Rampal, MD, PhD, Neal Rosen, MD PhD, Tanja A. Gruber, MD PhD, Omar Abdel-Wahab

Blood (2015) 126 (23): 481.

https://doi.org/10.1182/blood.V126.23.481.481

Published: 2015

Journal Articles

Concomitantly Targeting BCL-2 with Venetoclax (ABT-199/GDC-0199) and MAPK Signaling with Cobimetinib (GDC-0973) in Acute Myeloid Leukemia Models

Lina Han, PhD, Qi Zhang, Ce Shi, PhD, Joel Leverson, PhD, Monique Dail, Darren C. Phillips, PhD, Jun Chen, MDPhD, Sha S Jin, Rodrigo Omar Jacamo, PhD, Naval Daver, MD, Elias J Jabbour, MD, Hagop M Kantarjian, MD, Michael Andreeff, MD PhD, Deepak Sampath, PhD, Marina Konopleva, MD PhD

Blood (2015) 126 (23): 2544.

https://doi.org/10.1182/blood.V126.23.2544.2544

Published: 2015

NARROW

Integrative Analysis of FISH, Transcriptomics and Mutational Status Predicts Responsiveness to Novel Agents in Multiple Myeloma

Therapeutic Stratification of PTEN-MYC Axis Appears to be Promising for Molecular Targeted Therapies in Refractory and Relapsed T-Cell Acute Lymphoblastic Leukemia

Classification and Prognosis of Central Nervous System Involvement in Erdheim-Chester Disease

Geriatric Assessment (GA) Measures and Patient-Reported Outcomes (PROs) Among Older Adults Treated in a Phase 1b Study for Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Characterizing Population Heterogeneity and Signaling Changes in Chronic Myeloid Leukemia Stem and Progenitor Cells upon Combined Treatment with Imatinib and MEK Inhibitors Using Quantitative Single Cell Phospho-Imaging

BCL-2 Inhibitor Venetoclax (ABT-199) and MEK Inhibitor GDC-0973 Synergise to Target AML Progenitors and Overcome Drug Resistance with the Use of PET Scanning in a Mouse Model of HR-MDS to Monitor Response to Treatment

Safety, Efficacy, Pharmacokinetic (PK) and Biomarker Analyses of BCL2 Inhibitor Venetoclax (Ven) Plus MDM2 Inhibitor Idasanutlin (idasa) in Patients (pts) with Relapsed or Refractory (R/R) AML: A Phase Ib, Non-Randomized, Open-Label Study

Preliminary Results from a Phase Ib Study Evaluating BCL-2 Inhibitor Venetoclax in Combination with MEK Inhibitor Cobimetinib or MDM2 Inhibitor Idasanutlin in Patients with Relapsed or Refractory (R/R) AML

Phase 2 Trial of Single-Agent Cobimetinib for Adults with BRAF V600-Mutant and Wild-Type Histiocytic Disorders

BCL-2 Inhibition with ABT-199 Shows Efficacy in AML Cell Lines with Synergistic Effects upon Addition of the MEK Inhibitor GDC-0973 and Prolongs Survival in an NAS/BCL-2-Mediated Mouse Model of AML Post-MDS

Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study)

PI3K and MEK Inhibition in Hypodiploid Acute Lymphoblastic Leukemia

Upregulation of MAPK/MCL-1 Maintaining Mitochondrial Oxidative Phosphorylation Confers Acquired Resistance to BCL-2 Inhibitor Venetoclax in AML

Targeting MAPK Signaling Pathway with Cobimetinib (GDC-0973) Enhances Anti-Leukemia Efficacy of Venetoclax (ABT-199/GDC-0199) in Acute Myeloid Leukemia Models

Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms

Concomitantly Targeting BCL-2 with Venetoclax (ABT-199/GDC-0199) and MAPK Signaling with Cobimetinib (GDC-0973) in Acute Myeloid Leukemia Models

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only